# Phase 2 Study of Darbepoetin Alfa Extended Dosing

> **NCT00527215** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 98 (actual)

## Conditions studied

- Pre-Dialysis

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00527215
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2009-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527215, "Phase 2 Study of Darbepoetin Alfa Extended Dosing". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00527215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*